# Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

> **NCT00984113** · PHASE1 · TERMINATED · sponsor: **Portola Pharmaceuticals** · enrollment: 44 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** Elinogrel

## Key facts

- **NCT ID:** NCT00984113
- **Lead sponsor:** Portola Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** For administrative reasons. Enrollment was sufficient to have statistical power without compromising the integrity of the study data
- **Last updated:** 2023-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00984113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00984113, "Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00984113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*